Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic
ContributorsAltomare, Daniele ; Stampacchia, Sara ; Ribaldi, Federica; Tomczyk, Szymon; Chevalier, Claire; Poulain, Géraldine; Asadi, Saina; Bancila, Bianca; Marizzoni, Moira; Martins, Marta; Lathuilière, Aurélien ; Scheffler, Max ; Ashton, Nicholas J; Zetterberg, Henrik ; Blennow, Kaj; Kern, Ilse; Frias, Miguel ; Garibotto, Valentina ; Frisoni, Giovanni
Published inJournal of neurology, neurosurgery and psychiatry, vol. 94, no. 6, p. 420-427
Publication date2023-06
First online date2023-04-03
Abstract
Keywords
- CSF
- PET
- Alzheimer's disease
- Dementia
- Memory
- Humans
- Alzheimer Disease / diagnostic imaging
- Tau Proteins / cerebrospinal fluid
- Amyloid beta-Peptides / cerebrospinal fluid
- Biomarkers / cerebrospinal fluid
- Positron-Emission Tomography
- Peptide Fragments / cerebrospinal fluid
- Cognitive Dysfunction / diagnosis
Affiliation entities
- Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale
- Centres et instituts / Centre interfacultaire de neurosciences
- Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie
- Faculté de médecine / Section de médecine clinique / Département de médecine
Funding
- Swiss National Science Foundation - The Biological Basis of Cognitive Impairment due to Suspected Non-Alzheimer’s Pathology (SNAP) : Studying the interplay between amyloidosis and tau-related neurodegeneration [169876]
- Swiss National Science Foundation - Individual cognitive risk profiling in aging according to Amyloid, Tau and Neurodegeneration imaging biomarkers [185028]
- Swiss National Science Foundation - Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): correlation with clinical features and in vivo neuropathology [182772]
- Swiss National Science Foundation - CLearing Alzheimer’s disease Molecular Pathology without medications (CLAMP) [196354]
- Swiss National Science Foundation - Individual cognitive risk profiling in aging according to Amyloid, Tau and Neurodegeneration imaging biomarkers [185028]
- European Commission - Study of tau strains to understand the phenotypic diversity of Alzheimer’s disease: A step toward personalized therapies [839098]
- Swedish Research Counci - [2018-02532]
- European Commission - Pathways to Alzheimer's disease [681712]
- European Commission - Fluid Biomarkers for Neurodegenerative Dementias [101053962]
- Swedish State Support for Clinical Research - [ALFGBG-71320]
- Alzheimer Drug Discovery Foundation (ADDF) - [201809-2016862]
- Alzheimer's Association - [#AACSF-19-617308 & #ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C]
- European Commission - Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis [860197]
- Swiss National Science Foundation - Strategic roadmap for the translation of tau biomarkers in the clinic: an international task force [188355]
- Velux foundation - [1123]
- European Commission - European Prevention of Alzheimer’s Dementia Consortium [115736]
- European Commission - Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952 [115952]
Citation (ISO format)
ALTOMARE, Daniele et al. Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic. In: Journal of neurology, neurosurgery and psychiatry, 2023, vol. 94, n° 6, p. 420–427. doi: 10.1136/jnnp-2022-330619
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:169897
- DOI : 10.1136/jnnp-2022-330619
- PMID : 37012066
- PMCID : PMC10314086
Commercial URLhttps://jnnp.bmj.com/content/94/6/420
ISSN of the journal0022-3050